MET, AM25C, MROH9, MYEOV, FAM111B, Y6D, and PPP2R3A were highly expressed in the high-risk group, indicating that these genes may be related to the oncology process for patients with PAAD, and they seemed to be cancer-promoting genes. Here, MYEOV is linked to pancreatic adenocarcinoma.